Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA TrialBenoit You, Patrick Robelin, Michel Tod, et al.
The Lancet. Oncology|July 10, 2023
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trialJean-Yves Blay, Sylvie Chevret, Axel Le Cesne, et al.
American Journal of Obstetrics and Gynecology|October 6, 2024
FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasiaAdrien Msika, Virginie Mathias, Marina Boudigou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2023
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 TrialJean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, et al.
Translational Oncology|July 1, 2026
Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trialPauline Corbaux, Olivier Colomban, Gaelle Lescuyer, et al.
Gynecologic Oncology|January 27, 2023
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trialGwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Becourt, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 21, 2023
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2024
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III TrialAntonio González-Martín, María Jesús Rubio, Florian Heitz, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2020
A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countriesYazid Belkacemi, Noemie Grellier, Sahar Ghith, et al.
Pageof 9